Price
No data yet.
Social Signal Score
Analyst Ratings
45 analystsRevenue
$4.37B+191.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ari Bousbib
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 94,000
- Beta
- 1.19
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.18
Financials
Revenue
$4.37B+191.8%Net Income
$256.00M+156.0%EBITDA
$790.00M+291.1%Free Cash Flow
$360.00M+50.3%EPS (diluted)
$1.53+86.6%Shares Outstanding (diluted)
168.60M+39.2%Operating Expenses
$574.00MCash & Debt
$2.08BReturn of Capital
$398.00MRevenue by Segment (annual)
$16.31BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.31B | $1.36B | $7.91 |
| 2024 | $15.40B | $1.37B | $7.57 |
| 2023 | $14.98B | $1.36B | $7.39 |
| 2022 | $14.41B | $1.09B | $5.82 |
| 2021 | $13.87B | $966.00M | $5.05 |
| 2020 | $11.36B | $279.00M | $1.46 |
| 2019 | $11.09B | $191.00M | $0.98 |
| 2018 | $10.41B | $259.00M | $1.27 |
| 2017 | $9.70B | $1.31B | $6.01 |
| 2016 | $6.82B | $115.00M | $0.77 |
| 2015 | $5.74B | $387.20M | $3.15 |
| 2014 | $5.46B | $356.38M | $2.78 |
| 2013 | $5.10B | $226.59M | $1.83 |
| 2012 | $4.87B | $177.55M | $1.42 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IQV's reported EPS growth of 14.1% a year over 13 years.
- EPS in 5 years
- $15.30
- Implied price
- $428.40
- Return from $258.21
- 10.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $212.99 — -17.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| 4.1% | -5.6% | -2.1% | 1.0% | 3.7% | 6.2% |
| 9.1% | -1.1% | 2.6% | 5.8% | 8.7% | 11.3% |
| 14.1% | 3.5% | 7.3% | 10.7% | 13.7% | 16.4% |
| 19.1% | 8.0% | 12.0% | 15.5% | 18.6% | 21.5% |
| 24.1% | 12.5% | 16.7% | 20.4% | 23.6% | 26.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-6.67%Social Signal Score
Mentions (14)
- Newszacks.com·3d ago·Positive
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
View source ↗ - News (Marketaux)gurufocus.com·12d ago·Negative
IQVIA Holdings (IQV) Completes $2 Billion Senior Notes Offering to Refinance Debt IQVIA Holdings Inc[+304 characters]
View source ↗ - Newszacks.com·19d ago·Neutral
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
View source ↗ - News (RSS)investing·20d ago·Neutral
IQVIA Holdings stock hits 52-week high at 271.82 USD
View source ↗ - News (RSS)yahoo·20d ago·Positive
A Strong Rebound Case of IQVIA Holdings (IQV)
View source ↗ - Newszacks.com·24d ago·Positive
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)yahoo·25d ago·Positive
IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
IQVIA prices $2B of senior notes due 2034
View source ↗ - News (Marketaux)gurufocus.com·31d ago·Positive
IQVIA (IQV) Insider James Berkshire Sells 2,668 Shares James Berkshire, an insider at IQVIA[+222 characters]
View source ↗ - News (RSS)investing·32d ago·Neutral
IQVIA launches AI platform for clinical trial development
View source ↗ - News (RSS)investing·33d ago·Neutral
IQVIA stock hits 52-week high at 265.29 USD
View source ↗ - Newszacks.com·39d ago·Neutral
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report? IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·40d ago·Positive
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
View source ↗ - Newszacks.com·54d ago·Positive
IQV Stock Gains 42% in 3 Months: Here's What You Should Know IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $3.27 per share
Typical surprise +1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$3.15 vs $3.03beat
- Tue, May 5$2.90 vs $2.82beat
- Thu, Feb 5$3.42 vs $3.40beat
- Tue, Oct 28$3.00 vs $2.98beat
- Tue, Jul 22$2.81 vs $2.77beat
- Tue, May 6$2.70 vs $2.63beat
Estimates and results for IQV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IQV officers and directors.
- Bought
- —
- Sold
- $38.0m
0 trades
10 trades
- Berkshire James G.sold
- Staub W Richardsold
- Patel Bhaviksold
- Sherbet Ericsold
- Cherofsky Keriannsold
- Bousbib Arisold
- Bousbib Arisold
- Bousbib Arisold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (20d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (25d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (14d later)Sell$15,001 - $50,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (21d later)Sell$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Jan 16, 2026 (18d later)Buy$15,001 - $50,000
- John Boozmansenate · AR · disclosed Nov 15, 2025 (44d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Feb 27, 2025 (14d later)Buy$15,001 - $50,000
- Markwayne Mullinsenate · OK · disclosed Sep 19, 2024 (30d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (20d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed May 26, 2023 (17d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.